Trials begin of VNS (vagus nerve stimulator) in obesity and Alzheimer's:
This article was originally published in Clinica
Executive Summary
Researchers have carried out the first human implants in studies to assess Cyberonics' vagus nerve stimulator as a treatment for two new indications - Alzheimer's disease and obesity. The NeuroCybernetic Prosthesis, which is already FDA-approved for treating epilepsy, was last month implanted in the first of six patients, as part of the first phase of a US study to assess the device in people with obesity. The Houston, Texas-based company said that the first of 10 Alzheimer's patients scheduled to take part in a pilot study in Sweden also received the device last month.